Literature DB >> 19357966

Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma.

Susan M Chang1, Sarah Nelson, Scott Vandenberg, Soonmee Cha, Michael Prados, Nicholas Butowski, Michael McDermott, Andrew T Parsa, Manish Aghi, Jennifer Clarke, Mitchel Berger.   

Abstract

PURPOSE: To integrate standard anatomic magnetic resonance imaging in conjunction with uniformly acquired physiologic imaging biomarkers of untreated glioma with different histological grades with the goal of generating an algorithm that can be applied for patient management.
METHODS: A total of 143 patients with previously untreated glioma were scanned immediately before surgical resection using conventional anatomical MR imaging, and with uniform acquisition of perfusion-weighted imaging, diffusion-weighted imaging, and proton MR spectroscopic imaging. Regions of interest corresponding to anatomic and metabolic lesions were identified to assess tumor burden. MR parameters that had been found to be predictive of survival in patients with grade IV glioma were evaluated as a function of tumor grade and histological sub-type. Based on these finding both anatomic and physiologic imaging parameters were then integrated to generate an algorithm for management of patients with newly diagnosed presumed glioma.
RESULTS: Histological analysis indicated that the population comprised 56 patients with grade II, 31 with grade III, and 56 with grade IV glioma. Based on standard anatomic imaging, the presence of hypointense necrotic regions in post-Gadolinium T1-weighted images and the percentage of the T2 hyperintense lesion that was either enhancing or necrotic were effective in identifying patients with grade IV glioma. The individual parameters of diffusion and perfusion parameters were significantly different for patients with grade II astrocytoma versus oligodendroglioma sub-types. All tumors had regions with elevated choline to N-acetylasparate index (CNI). Lactate was higher for grade III and grade IV glioma and lipid was significantly elevated for grade IV glioma. These results were integrated into a proposed management algorithm for newly diagnosed glioma that will need to be prospectively tested in future studies.
CONCLUSION: Metabolic and physiologic imaging characteristics provide information about tumor heterogeneity that may be important for assisting the surgeon to ensure acquisition of representative histology. Correlation of these integrated MR parameters with clinical features will need to be assessed with respect to their role in predicting outcome and stratifying patients into risk groups for clinical trials. Future studies will use image directed tissue sampling to confirm the biological interpretation of these parameters and to assess how they change in response to therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357966      PMCID: PMC2834319          DOI: 10.1007/s11060-009-9845-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  45 in total

1.  Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors.

Authors:  S J Nelson
Journal:  Magn Reson Med       Date:  2001-08       Impact factor: 4.668

Review 2.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging.

Authors:  Soonmee Cha; Edmond A Knopp; Glyn Johnson; Stephan G Wetzel; Andrew W Litt; David Zagzag
Journal:  Radiology       Date:  2002-04       Impact factor: 11.105

3.  Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence.

Authors:  Tracy R McKnight; Mary H von dem Bussche; Daniel B Vigneron; Ying Lu; Mitchel S Berger; Michael W McDermott; William P Dillon; Edward E Graves; Andrea Pirzkall; Sarah J Nelson
Journal:  J Neurosurg       Date:  2002-10       Impact factor: 5.115

4.  Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma".

Authors:  Hikaru Sasaki; Magdalena C Zlatescu; Rebecca A Betensky; Loki B Johnk; Andrea N Cutone; J Gregory Cairncross; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2002-01       Impact factor: 3.685

5.  An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma.

Authors:  T R McKnight; S M Noworolski; D B Vigneron; S J Nelson
Journal:  J Magn Reson Imaging       Date:  2001-02       Impact factor: 4.813

Review 6.  Treatment of malignant glioma: a problem beyond the margins of resection.

Authors:  A Giese; M Westphal
Journal:  J Cancer Res Clin Oncol       Date:  2001-04       Impact factor: 4.553

7.  Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors.

Authors:  D Vigneron; A Bollen; M McDermott; L Wald; M Day; S Moyher-Noworolski; R Henry; S Chang; M Berger; W Dillon; S Nelson
Journal:  Magn Reson Imaging       Date:  2001-01       Impact factor: 2.546

8.  Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma.

Authors:  R K Gupta; T F Cloughesy; U Sinha; J Garakian; J Lazareff; G Rubino; L Rubino; D P Becker; H V Vinters; J R Alger
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

9.  Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma.

Authors:  D Croteau; L Scarpace; D Hearshen; J Gutierrez; J L Fisher; J P Rock; T Mikkelsen
Journal:  Neurosurgery       Date:  2001-10       Impact factor: 4.654

10.  MR-spectroscopy guided target delineation for high-grade gliomas.

Authors:  A Pirzkall; T R McKnight; E E Graves; M P Carol; P K Sneed; W W Wara; S J Nelson; L J Verhey; D A Larson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-15       Impact factor: 7.038

View more
  24 in total

1.  Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

Authors:  Soléakhéna Ken; Alexandra Deviers; Thomas Filleron; Isabelle Catalaa; Jean-Albert Lotterie; Jonathan Khalifa; Vincent Lubrano; Isabelle Berry; Patrice Péran; Pierre Celsis; Elizabeth Cohen-Jonathan Moyal; Anne Laprie
Journal:  J Neurooncol       Date:  2015-07-19       Impact factor: 4.130

Review 2.  Interrogating Metabolism in Brain Cancer.

Authors:  Travis C Salzillo; Jingzhe Hu; Linda Nguyen; Nicholas Whiting; Jaehyuk Lee; Joseph Weygand; Prasanta Dutta; Shivanand Pudakalakatti; Niki Zacharias Millward; Seth T Gammon; Frederick F Lang; Amy B Heimberger; Pratip K Bhattacharya
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-11       Impact factor: 2.266

3.  Assessing Amide Proton Transfer (APT) MRI Contrast Origins in 9 L Gliosarcoma in the Rat Brain Using Proteomic Analysis.

Authors:  Kun Yan; Zongming Fu; Chen Yang; Kai Zhang; Shanshan Jiang; Dong-Hoon Lee; Hye-Young Heo; Yi Zhang; Robert N Cole; Jennifer E Van Eyk; Jinyuan Zhou
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

4.  Improved spatial coverage for brain 3D PRESS MRSI by automatic placement of outer-volume suppression saturation bands.

Authors:  Eugene Ozhinsky; Daniel B Vigneron; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2011-04       Impact factor: 4.813

5.  Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival.

Authors:  Valeria Cuccarini; A Erbetta; M Farinotti; L Cuppini; F Ghielmetti; B Pollo; F Di Meco; M Grisoli; G Filippini; G Finocchiaro; M G Bruzzone; M Eoli
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

6.  Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma.

Authors:  Fumiyuki Yamasaki; Kaoru Kurisu; Yoshinori Kajiwara; Yosuke Watanabe; Takeshi Takayasu; Yuji Akiyama; Taiichi Saito; Ryosuke Hanaya; Kazuhiko Sugiyama
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

7.  MR imaging of high-grade brain tumors using endogenous protein and peptide-based contrast.

Authors:  Zhibo Wen; Shuguang Hu; Fanheng Huang; Xianlong Wang; Linglang Guo; Xianyue Quan; Silun Wang; Jinyuan Zhou
Journal:  Neuroimage       Date:  2010-02-24       Impact factor: 6.556

8.  Growth properties of SF188/V+ human glioma in rats in vivo observed by magnetic resonance imaging.

Authors:  Rachel Grossman; Betty Tyler; Henry Brem; Charles G Eberhart; Silun Wang; De-Xue Fu; Zhibo Wen; Jinyuan Zhou
Journal:  J Neurooncol       Date:  2012-09-27       Impact factor: 4.130

9.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Authors:  Kathleen M Schmainda; Zheng Zhang; Melissa Prah; Bradley S Snyder; Mark R Gilbert; A Gregory Sorensen; Daniel P Barboriak; Jerrold L Boxerman
Journal:  Neuro Oncol       Date:  2015-02-02       Impact factor: 12.300

10.  Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement.

Authors:  Jinyuan Zhou; He Zhu; Michael Lim; Lindsay Blair; Alfredo Quinones-Hinojosa; Steven A Messina; Charles G Eberhart; Martin G Pomper; John Laterra; Peter B Barker; Peter C M van Zijl; Jaishri O Blakeley
Journal:  J Magn Reson Imaging       Date:  2013-02-25       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.